132 related articles for article (PubMed ID: 11317206)
1. Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets.
Jagroop IA; Mikhailidis DP
J Hum Hypertens; 2001 Mar; 15(3):203-7. PubMed ID: 11317206
[TBL] [Abstract][Full Text] [Related]
2. Platelet shape change in whole blood: differential effects of endotoxin.
Nystrom ML; Barradas MA; Jeremy JY; Mikhailidis DP
Thromb Haemost; 1994 May; 71(5):646-50. PubMed ID: 8091394
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved?
Siddiqui EJ; Shabbir M; Thompson CS; Mumtaz FH; Mikhailidis DP
Anticancer Res; 2005; 25(6B):4281-6. PubMed ID: 16309229
[TBL] [Abstract][Full Text] [Related]
4. Increased platelet purinergic sensitivity in peripheral arterial disease--a pilot study.
Braun OO; Jagroop A; Wang L; Mikhailidis DP; Burnstock G; Erlinge D
Platelets; 2005 Aug; 16(5):261-7. PubMed ID: 16011976
[TBL] [Abstract][Full Text] [Related]
5. Does meta-chlorophenylpiperazine (mCPP) activate human platelets?
Frampton AE; Andrews JC; Parfitt A; Jagroop IA; Mikhailidis DP; Henry JA
Platelets; 2006 Feb; 17(1):30-6. PubMed ID: 16308184
[TBL] [Abstract][Full Text] [Related]
6. The effect of tirofiban on fibrinogen/agonist-induced platelet shape change and aggregation.
Jagroop IA; Mikhailidis DP
Clin Appl Thromb Hemost; 2008 Jul; 14(3):295-302. PubMed ID: 18445610
[TBL] [Abstract][Full Text] [Related]
7. Platelet serotonin-LDL interaction in essential hypertension.
Amstein R; Fetkovska N; Bühler FR
J Cardiovasc Pharmacol; 1991; 17 Suppl 5():S35-40. PubMed ID: 1717771
[TBL] [Abstract][Full Text] [Related]
8. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
9. Effect of doxazosin gastrointestinal therapeutic system on platelet degranulation and platelet-leukocyte microaggregate formation induced by physiologic shear stress in hypertension.
Labiós M; Martínez M; Gabriel F; Guiral V; Aznar J
Thromb Res; 2006; 118(4):447-53. PubMed ID: 16242179
[TBL] [Abstract][Full Text] [Related]
10. Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy.
Ikeda T; Gomi T; Shibuya Y; Shinozaki S; Suzuki Y; Matsuda N
Hypertens Res; 2007 Nov; 30(11):1097-105. PubMed ID: 18250559
[TBL] [Abstract][Full Text] [Related]
11. Chronic alpha-1-adrenergic blockade increases sympathoneural but not adrenomedullary activity in patients with essential hypertension.
Jacobs MC; Lenders JW; Willemsen JJ; Thien T
J Hypertens; 1995 Dec; 13(12 Pt 2):1837-41. PubMed ID: 8903663
[TBL] [Abstract][Full Text] [Related]
12. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Kyprianou N
J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
[TBL] [Abstract][Full Text] [Related]
13. Activation of the alpha(2A)-adrenoceptor mediates deceleration of the deaggregation component of the response to ADP or 5-HT in human platelets in vitro.
Maayani S; Schwarz T; Craddock-Royal B; Tagliente TM
Platelets; 2001 Sep; 12(6):359-75. PubMed ID: 11672475
[TBL] [Abstract][Full Text] [Related]
14. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease.
Jagroop IA; Matsagas MI; Geroulakos G; Mikhailidis DP
Platelets; 2004 Mar; 15(2):117-25. PubMed ID: 15154604
[TBL] [Abstract][Full Text] [Related]
15. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
Chung BH; Hong SJ; Lee MS
Int J Urol; 2005 Feb; 12(2):159-65. PubMed ID: 15733110
[TBL] [Abstract][Full Text] [Related]
16. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Keledjian K; Kyprianou N
J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
18. Differential actions of naftopidil, doxazosin and nifedipine on platelet thromboxane generation and platelet-derived growth factor efflux in vitro.
Alarayyed NA; Prichard BN; Betteridge DJ; Smith CC
Platelets; 2002; 13(5-6):267-71. PubMed ID: 12189011
[TBL] [Abstract][Full Text] [Related]
19. [Effects of doxazosin enantiomers on alpha-adrenoceptors of isolated rabbit blood vessels].
Lu HG; Liu LF; Ren LM; Zhao QH; Duan LH; Zhang XY
Yao Xue Xue Bao; 2007 Feb; 42(2):145-51. PubMed ID: 17518041
[TBL] [Abstract][Full Text] [Related]
20. Age and the platelet serotonin vasoconstrictor axis in essential hypertension.
Amstein R; Fetkovska N; Lüscher TF; Kiowski W; Bühler FR
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S35-40. PubMed ID: 2459512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
